Press – Maiwald

Press Coverage

14 Jul 2025 - Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

9 Jul 2025 - Press Coverage

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.

24 Jun 2025 - Press Coverage

Maiwald Advises Royalty Pharma on $2 Billion Funding Agreement with Revolution Medicines

Maiwald acted as legal advisor to Royalty Pharma in connection with an innovative funding agreement totaling up to $2 billion with Revolution Medicines. The transaction includes up to $1.25 billion in synthe...

All press coverage

Maiwald press releases

24 Jun 2025 - Press Release

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

17 Jun 2025 - Press Release

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

In a significant development, the European Patent Office (EPO) has revoked Salix Pharmaceuticals’ European patent for the antibiotic rifaximin. In decision T 0162/22, the EPO Board of Appeal confirmed the revocation of European Patent EP 2 252 148 following the wit...

20 Dec 2022 - Press Release

Maiwald wins important opposition case for its client Acetate International LLC at the European Patent Office

Maiwald GmbH in Munich has achieved an important victory for its client Acetate International LLC at the European Patent Office. Acetate International LLC is part of the Celanese group which has a long history of producing cellulose acetate products for commercial applicatio...

All press releases

Maiwald in the press

Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

Maiwald Advises Royalty Pharma on $2 Billion Funding Agreement with Revolution Medicines

Maiwald press releases

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

Maiwald wins important opposition case for its client Acetate International LLC at the European Patent Office

Press Contact

Dr. Eva Dörner